Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $12.64 million. The enterprise value is -$1.00 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, before market open.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 7.06 million shares outstanding. The number of shares has increased by 439.67% in one year.
Current Share Class | 7.06M |
Shares Outstanding | 7.06M |
Shares Change (YoY) | +439.67% |
Shares Change (QoQ) | -19.32% |
Owned by Insiders (%) | 5.19% |
Owned by Institutions (%) | 9.31% |
Float | 6.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.74 |
Forward PS | 98.69 |
PB Ratio | 1.42 |
P/TBV Ratio | 1.46 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09
Current Ratio | 2.09 |
Quick Ratio | 1.96 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -248.20% and return on invested capital (ROIC) is -176.40%.
Return on Equity (ROE) | -248.20% |
Return on Assets (ROA) | -73.84% |
Return on Invested Capital (ROIC) | -176.40% |
Return on Capital Employed (ROCE) | -245.05% |
Revenue Per Employee | $414,714 |
Profits Per Employee | -$728,286 |
Employee Count | 7 |
Asset Turnover | 0.17 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.39% in the last 52 weeks. The beta is 1.52, so Traws Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.52 |
52-Week Price Change | -80.39% |
50-Day Moving Average | 1.52 |
200-Day Moving Average | 3.35 |
Relative Strength Index (RSI) | 70.38 |
Average Volume (20 Days) | 160,520 |
Short Selling Information
The latest short interest is 162,903, so 2.31% of the outstanding shares have been sold short.
Short Interest | 162,903 |
Short Previous Month | 96,639 |
Short % of Shares Out | 2.31% |
Short % of Float | 2.70% |
Short Ratio (days to cover) | 1.29 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $2.90 million and -$5.10 million in losses. Loss per share was -$1.07.
Revenue | 2.90M |
Gross Profit | 2.90M |
Operating Income | -20.27M |
Pretax Income | -18.16M |
Net Income | -5.10M |
EBITDA | -20.26M |
EBIT | -20.27M |
Loss Per Share | -$1.07 |
Full Income Statement Balance Sheet
The company has $13.08 million in cash and n/a in debt, giving a net cash position of $13.08 million or $1.85 per share.
Cash & Cash Equivalents | 13.08M |
Total Debt | n/a |
Net Cash | 13.08M |
Net Cash Per Share | $1.85 |
Equity (Book Value) | 8.26M |
Book Value Per Share | 1.17 |
Working Capital | 8.02M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -26.93M |
Capital Expenditures | n/a |
Free Cash Flow | -26.93M |
FCF Per Share | -$3.81 |
Full Cash Flow Statement Margins
Gross Margin | 100.00% |
Operating Margin | -698.11% |
Pretax Margin | -613.92% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -439.67% |
Shareholder Yield | -439.67% |
Earnings Yield | -42.20% |
FCF Yield | -222.96% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.
Last Split Date | Sep 23, 2024 |
Split Type | Reverse |
Split Ratio | 1:25 |
Scores
Traws Pharma has an Altman Z-Score of -58.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -58.71 |
Piotroski F-Score | 2 |